Part Three: Rapid LVV Titer Determination With The Virus Counter Plus Platform

By Poorni Adikaram, Ph.D., Tyler Frazier, and Timothy Fouts, Ph.D., CSO, at ABL Inc- . and Rebecca Montange, Ph.D, and Brandon Harrell at Sartorius

As the need for lentiviral vectors (LVVs) continues to grow, so does the demand for scalable and reliable GMP manufacturing solutions. One of the main obstacles to accelerating process development is the limited availability of rapid and consistent LVV quantification methods. The Virus Counter® Plus platform from Sartorius, combined with the Virotag® VSVG assay, addresses this challenge by enabling fast, accurate measurement of total viral particles — supporting the efficient development of optimized manufacturing workflows.

In this three-part blog series, ABL, Inc. scientists examine the shortcomings of existing titer measurement approaches, introduce the Virus Counter Plus technology, and highlight results from a joint study with Sartorius. The study compares titer data obtained using this novel method with results from standard physical and functional assays.